Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of (a) repealing or (b) amending Section 2(4) of the Law Reform (Personal Injuries) Act 1948.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the recently published 10-Year Health Plan for England, David Lock KC will be providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims, ahead of a review by the Department in the autumn.
The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Civil Procedure Rule Committee on the implementation of fixed recoverable costs in clinical negligence claims valued up to £25,000.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the recently published 10-Year Health Plan for England, David Lock KC will be providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims, ahead of a review by the Department in the autumn.
The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help lower (a) legal and (b) overall costs incurred through clinical negligence.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the recently published 10-Year Health Plan for England, David Lock KC will be providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims, ahead of a review by the Department in the autumn.
The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of designating group B Streptococcus as a notifiable disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Health Security Agency (UKHSA) does not recommend adding Group B Streptococcus as a notifiable disease. Existing national surveillance effectively captures Group B Streptococcus infections, monitors trends, and informs antibiotic prescribing policy. The UKHSA has assessed that mandatory notification for Group B Streptococcus would provide no additional public health benefit beyond this.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his planned timeline is for the data collection, evaluation and interim decision for the in-service evaluation of newborn screening for spinal muscular atrophy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On all aspects of population and targeted screening, Ministers are advised by the UK National Screening Committee (UK NSC).
The UK NSC recommended an in-service evaluation (ISE) of newborn blood spot screening for spinal muscular atrophy (SMA) in National Health Services in 2023. Since then, the SMA Newborn Screening ISE Partnership Board was set up to plan and develop work to shape the ISE, and progress is being made. This includes planning the duration of the ISE and planning for newborn laboratories to screen blood spot samples for SMA. The laboratories in England that will form part of the ISE are under consideration by the SMA partnership board led by NHS England. The researchers and the National Institute for Health and Research (NIHR) will be responsible for determining the number of babies and services that will be required to answer the research questions.
Earlier in the year, the NIHR published their Health Technology Assessment research brief to appoint researchers for this work. Applications closed at the end of September 2025, and final funding decisions are expected in spring 2026. A decision on the shape and roll out of the ISE will be made after the research call process has concluded.
A recommendation by the UK NSC on newborn screening for SMA is expected following the conclusion of an ISE, which is needed to answer several outstanding questions related to the implementation of a screening programme for SMA.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how newborn screening laboratories can join the in-service evaluation of newborn screening for spinal muscular atrophy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On all aspects of population and targeted screening, Ministers are advised by the UK National Screening Committee (UK NSC).
The UK NSC recommended an in-service evaluation (ISE) of newborn blood spot screening for spinal muscular atrophy (SMA) in National Health Services in 2023. Since then, the SMA Newborn Screening ISE Partnership Board was set up to plan and develop work to shape the ISE, and progress is being made. This includes planning the duration of the ISE and planning for newborn laboratories to screen blood spot samples for SMA. The laboratories in England that will form part of the ISE are under consideration by the SMA partnership board led by NHS England. The researchers and the National Institute for Health and Research (NIHR) will be responsible for determining the number of babies and services that will be required to answer the research questions.
Earlier in the year, the NIHR published their Health Technology Assessment research brief to appoint researchers for this work. Applications closed at the end of September 2025, and final funding decisions are expected in spring 2026. A decision on the shape and roll out of the ISE will be made after the research call process has concluded.
A recommendation by the UK NSC on newborn screening for SMA is expected following the conclusion of an ISE, which is needed to answer several outstanding questions related to the implementation of a screening programme for SMA.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing a screening programme for group B Streptococcus in pregnant women.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On all aspects of population and targeted screening, Ministers are advised by the UK National Screening Committee (UK NSC).
The UK NSC last reviewed the evidence to screen for group B streptococcus (GBS) at 35 to 37 weeks of pregnancy in 2017 and concluded that there was insufficient evidence to demonstrate that the benefits of screening would outweigh the harms.
This was because the test currently available cannot accurately distinguish between those mothers whose babies are at risk and those who are not.
This means that many women would unnecessarily be offered antibiotics during labour, with the balance of harms and benefits from this approach being unknown.
The National Institute for Health Research funded a large-scale clinical trial to compare universal screening for GBS against the usual risk factor-based strategy.
Recruitment to the trial ended in March 2024 and a report is expected in early 2026. The UK NSC Secretariat is in contact with the researchers. The UK NSC will review its recommendation considering the evidence from the trial, after the report is presented.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when his Department plans to confirm the funding settlement for Start for Life services from 1 April 2026; whether that funding settlement will include the (a) increased geography and (b) widened age range of the programme; and whether ring-fenced funding will be allocated to provide (i) parent-infant relationship support, (ii) perinatal mental health support and (iii) infant feeding services.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan sets out an ambitious agenda for a decade of renewal to create a new model of care to improve the nation’s health. Over the next decade, we will give every child the best start in life by expanding Start for Life services and by integrating zero-to-five-year old’s health and children’s services within communities, with a strong focus on the critical first 1,001 days.
Building on the £126 million funding boost for the Family Hubs and Start for Life programme in 2025/26, an additional £500 million will enable Best Start Family Hubs to be rolled out to every local authority from April 2026.
The Government recognises the importance of providing local authorities with certainty on financial allocations and we will communicate outcomes, including grant details and delivery expectations where applicable, with local authorities when we have more information to share.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) mental and (b) physical health benefits of having access to (i) green and (ii) blue spaces for recreation.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The ability to access green and blue space is associated with improved physical and mental health and increased healthy life expectancy.
The Government recognises the importance of providing access to the outdoors for people's health and wellbeing, and has committed to creating nine new national river walks and three new national forests in England, expanding access to the great outdoors.
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of integrating OpenActive data standards into NHS clinical care pathways.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Health and Social Care Act 2022, the Data (Use and Access) Act 2025 and the Health and Social Care Information Standards (Procedure) Regulations 2025 establish a new legislative framework for setting mandatory information standards for public and private health and adult social care providers and IT suppliers in the health and care system. This will provide the basis for ensuring interoperability between IT systems.
Standards will be introduced in a staged process following the procedure set out in the Health and Social Care Information Standards (Procedure) Regulations 2025. No assessment has yet been made of the potential of the OpenActive data standards.